Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 1, 2011, Pages 215-221

  Feliu, J ^a   Borrega, P ^b   Leon A ^c   Lopez Gomez L ^d   Lopez M ^e   Castro, J ^a   Belda Iniesta, C ^a   Barriuso, J ^a   Martinez V ^a   Gonzalez Baron M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b San Pedro de Alcantara Hospital   (Spain)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

Erlotinib; FDR; Gemcitabine; Pancreatic carcinoma

Indexed keywords

ERLOTINIB; GEMCITABINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; QUINAZOLINES; SURVIVAL; TREATMENT OUTCOME;

EID: 78651099803     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1472-0     Document Type: Article

References (31)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 581 592 1:STN:280:DC%2BD2s7hslSgtw%3D%3D 10.1093/annonc/mdl498 17287242 (Pubitemid 46359643)
3. A Sultana CT Smith D Cunningham N Starling JP Neoptolemos P Ghaneh 2007 Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer J Clin Oncol 25 2607 2615 10.1200/JCO.2006.09.2551 17577041 (Pubitemid 47041235)
4. HA Burris MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 1:CAS:528:DyaK2sXlsFKksLY%3D 9196156
5. GK Abou-Alfa R Letourneau G Harker M Modiano H Hurwitz NS Tchekmedyian K Feit J Ackerman RL De Jager SG Eckhardt EM O'Reilly 2006 Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer J Clin Oncol 24 4414 4417
6. D Cunningham I Chau DD Stocken JW Valle D Smith W Steward PG Harper J Dunn C Tudur-Smith J West S Falk A Crellin F Adab J Thompson P Leonard J Ostrowski M Eatock W Scheithauer R Herrmann JP Neoptolemos 2009 Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer J Clin Oncol 27 33 5513 5518 1:CAS:528:DC%2BC3cXhtVWitrc%3D 10.1200/JCO.2009.24.2446 19858379
7. V Heinemann D Quietzsch F Gieseler M Gonnermann H Schonekas A Rost H Neuhaus C Haag M Clemens B Heinrich U Vehling-Kaiser M Fuchs D Fleckenstein W Gesierich D Uthgenannt H Einsele A Holstege A Hinke A Schalhorn R Wilkowski 2006 Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 3946 3952 1:CAS:528:DC%2BD28Xps1Sit78%3D 10.1200/JCO.2005.05.1490 16921047 (Pubitemid 46630743)
8. HL Kindler D Niedzwiecki D Hollis E Oraefo D Schrag H Hurwitz HL McLeod MF Mulcahy RL Schilsky RM Goldberg 2007 A double-blind, placebo controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a prelminary analysis of Cancer and Leukemia Group B (CALGB) Proc Am Soc Clin Oncol 25 18s (abstr 4508)
9. C Louvet R Labianca P Hammel G Lledo MG Zampino T Andre A Zaniboni M Ducreux E Aitini J Taieb R Faroux C Lepere A de Gramont 2005 Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 3509 3516 1:CAS:528:DC%2BD2MXlsVyhsrg%3D 10.1200/JCO.2005.06. 023 15908661
10. H Oettle D Richards RK Ramanathan JL van Laethem M Peeters M Fuchs A Zimmermann W John D Von Hoff M Arning HL Kindler 2005 A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Ann Oncol 16 1639 1645 1:STN:280: DC%2BD2MvpvFKhsg%3D%3D 10.1093/annonc/mdi309 16087696 (Pubitemid 41510138)
11. PA Philip J Benedetti C Fenoglio-Preiser M Zalupski H Lenz E O'Reilly R Wong J Atkins J Abruzzese C Blanke 2007 Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study Proc Am Soc Clin Oncol 25 18s (abstr LBA4509)
12. CM Rocha Lima MR Green R Rotche WH Miller Jr GM Jeffrey LA Cisar A Morganti N Orlando G Gruia LL Miller 2004 Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 3776 3783 1:CAS:528:DC%2BD2cXhtVCitb%2FO 10.1200/JCO.2004.12.082 15365074 (Pubitemid 41095218)
13. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K Ding G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 1:CAS:528:DC%2BD2sXmvVWmsr0%3D 10.1200/JCO.2006.07.9525 17452677 (Pubitemid 46972777)
14. R Grunewald JL Abbruzzese P Tarassoff W Plunkett 1991 Saturation of 2,2-difluorodeoxycytidine 5-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine Cancer Chemother Pharmacol 27 258 262 1:STN:280:DyaK3M7lt1yitg%3D%3D 10.1007/BF00685109 1998982
15. SA Veltkamp JH Beijnen JH Schellens 2008 Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy Oncologist 13 261 276 1:CAS:528:DC%2BD1cXltlChsro%3D 10.1634/theoncologist.2007-0215 18378536 (Pubitemid 351679901)
16. N Touroutoglou D Gravel MN Raber W Plunkett JL Abbruzzese 1998 Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors Ann Oncol 9 1003 1008 1:STN:280: DyaK1M%2FjsFCgtw%3D%3D 10.1023/A:1008487932384 9818075 (Pubitemid 28496710)
17. M Tempero W Plunkett V Ruiz Van Haperen J Hainsworth H Hochster R Lenzi J Abbruzzese 2003 Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 3402 3408 1:CAS:528:DC%2BD2cXpsVKjtLs%3D 10.1200/JCO.2003.09.140 12885837 (Pubitemid 46594072)
18. BA Carneiro RE Brand E Fine RH Knop JD Khandekar W Uhlig GY Locker 2007 Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma Cancer Invest 25 366 371 1:CAS:528: DC%2BD2sXot1Gmsr8%3D 10.1080/15368370701357957 17661212 (Pubitemid 47185076)
19. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
20. T Fleming 1982 One-sample multiple testing procedure for phase II clinical trials Biometrics 38 143 151 1:STN:280:DyaL383gs12gsA%3D%3D 10.2307/2530297 7082756
21. E Poplin Y Feng J Berlin ML Rothenberg H Hochster E Mitchell S Alberts P O'Dwyer D Haller P Catalano D Cella AB Benson 2009 Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group J Clin Oncol 27 3778 3785 1:CAS:528:DC%2BD1MXhtFaitr3L 10.1200/JCO.2008.20.9007 19581537
22. MH Kulke MA Tempero D Niedzwiecki DR Hollis HL Kindler M Cusnir PC Enzinger SM Gorsch RM Goldberg RJ Mayer 2009 Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904 J Clin Oncol 27 5506 5512 1:CAS:528:DC%2BC3cXhtVWitrY%3D 10.1200/JCO.2009.22.1309 19858396
23. SS Ng MS Tsao T Nicklee DW Hedley 2002 Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma Mol Cancer Ther 1 777 783 1:CAS:528:DC%2BD3sXlslGkug%3D%3D 12492110
24. E Van Cutsem WL Vervenne J Bennouna Y Humblet S Gill JL Van Laethem C Verslype W Scheithauer A Shang J Cosaert MJ Moore 2009 Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer J Clin Oncol 27 2231 2237 10.1200/JCO.2008.20.0238 19307500
25. A Philip M Mooney D Jaffe G Eckhardt M Moore N Merepol L Emens E O'Reilly M Kork L Ellis J Benedetti M Rothenberg C Willet M Tempero A Lowy J Abbruzzese D Simeone S Hingorani J Berlin J Tepper 2009 Consensus report of the National Cancer Institute Clinical Trials planning meeting on pancreas cancer treatment J Clin Oncol 27 5660 5669 10.1200/JCO.2009.21.9022 19858397
26. MH Kulke LS Blaszkowsky DP Ryan JW Clark JA Meyerhardt AX Zhu PC Enzinger EL Kwak A Muzikansky C Lawrence CS Fuchs 2007 Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer J Clin Oncol 25 4787 4792 1:CAS:528:DC%2BD2sXhtlCgsLbO 10.1200/JCO.2007.11.8521 17947726 (Pubitemid 350086482)
27. B Wacker T Nagrani J Weinberg K Witt G Clark PJ Cagnoni 2007 Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies Clin Cancer Res 13 3913 3921 1:CAS:528:DC%2BD2sXntFymt78%3D 10.1158/1078-0432.CCR-06-2610 17606725 (Pubitemid 47037599)
28. H Ueno K Kiyosawa N Kaniwa 2007 Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer 97 145 151 1:CAS:528:DC%2BD2sXnsFaqsbk%3D 10.1038/sj.bjc.6603860 17595663 (Pubitemid 47057479)
29. E Giovannetti AC Laan E Vasile C Tibaldi S Nannizzi S Ricciardi A Falcone R Danesi GJ Peters 2008 Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples Nucleosides Nucleotides Nucleic Acids 27 720 725 1:CAS:528:DC%2BD1cXotFelsLw%3D 10.1080/15257770802145447 18600531 (Pubitemid 351948583)
30. E Giovannetti M Del Tacca V Mey N Funel S Nannizzi S Ricci C Orlandini U Boggi D Campani M Del Chiaro M Iannopollo G Bevilacqua F Mosca R Danesi 2006 Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine Cancer Res 66 3928 3935 1:CAS:528:DC%2BD28XjtVOqs7k%3D 10.1158/0008-5472.CAN-05-4203 16585222
31. E Sugiyama N Kaniwa SR Kim R Kikura-Hanajiri R Hasegawa K Maekawa Y Saito S Ozawa J Sawada N Kamatani J Furuse H Ishii T Yoshida H Ueno T Okusaka N Saijo 2007 Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism J Clin Oncol 25 32 42 1:CAS:528: DC%2BD2sXht1ejs78%3D 10.1200/JCO.2006.06.7405 17194903 (Pubitemid 350003048)